Published in:

01-10-2014 | Original Paper

Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy

Published in: Medical Oncology | Issue 10/2014